Hidden Brain iron content in Sickle cell disease: Impact on Neurocognitive Functions

Mohsen Saleh ElAlfy
  Ain Shams University Faculty of Medicine

Ahmed Samir Ibrahim
  Ain Shams University Faculty of Medicine

Ghada Samir Ibrahim (✉️ ghadasamir055@gmail.com)
  Ain Shams University Faculty of Medicine

Hanaa Midhat Abdel Gader Hussein
  Ain Shams University Faculty of Medicine

Hend Galal Eldeen Mohammed
  Ain Shams University Faculty of Medicine

Fatma Soliman Elsayed Ebeid (✉️ dr.fatma_ebeid@yahoo.com)
  Ain Shams University Faculty of Medicine  https://orcid.org/0000-0002-3761-6373

Research Article

Keywords: Brain iron overload, Sickle cell disease, T2* value, B thalassemia major

DOI: https://doi.org/10.21203/rs.3.rs-399346/v1

License: 😊 This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Children with sickle cell disease (SCD) are at a high risk for neurocognitive impairment. We aim to quantitatively measure cerebral tissue R2* to investigate the brain iron deposition in children and young adults with SCD in comparison to beta thalassemia major (BTM) and healthy controls and evaluate its impact on neurocognitive functions in patients with SCD. Thirty-two SCD, fifteen BTM and eleven controls were recruited. Multi-echo fast-gradient echo sequence brain MRI was performed and brain R2* values of both caudate and thalamic regions were calculated. SCD patients were examined for the neurocognitive functions. SCD had high iron overload 0.30±0.12 mg/kg/day. 68.9% of SCD had under-threshold IQ, 12.5% had moderate to severe anxiety and 60.8% had depression. There was no differences between SCD, BTM and controls in brain MRI except that left thalamus R2* higher in BTM than both SCD and controls (p=0.032). Mean right caudate R2* was higher in female than male (p=0.044). No significant association between brain R2* and LIC or heart R2* values in SCD. Left caudate R2* directly correlate with age and HbS%, negative correlate with HbA% while right thalamus R2* negatively correlate with transfusion index and among SCD patients. Conclusion: Neurocognitive dysfunction in SCD could not be explained solely by brain iron overload.

Introduction

Central nervous system (CNS) complications are among the most devastating manifestations of sickle cell disease (SCD) with approximately 250-fold higher incidence of stroke than in the general pediatric population. (1) Cerebrovascular accidents can be the cause of the observed neurocognitive impairments. (2) However, even in the absence of overt cerebral strokes or parenchymal abnormalities in neurologically intact SCD patients; neurocognitive dysfunction could occur (3) due to recurrent micro-infarction of the CNS, hypoxic damage to the brain secondary to chronic anemia, hypoxic damage exacerbated by acute events and chronic nutritional deficiency associated with increased metabolic demands. (2)

Elevated iron in the brain, in case of iron overload syndromes has a neurotoxic effect through the formation of reactive oxygen species (ROS) which are a source of oxidative stress that initiates apoptotic signal pathways. (4) Because the abundance of molecular oxygen and oxidizable neurotransmitters and the presence of poor antioxidant defense mechanisms of the brain, it becomes very liable for iron-induced oxidative damages. (5)

Owing to these observations, most recent evaluations of clinical trials to treat children with SCD have included neurocognitive function as a primary or secondary outcome. (6) It is clearly a priority of the pediatric SCD community to address concerns and better understand how neurocognitive function is affected and how to prevent this devastating impact from happening. (7) Primary objective of this work was to measure quantitative brain brain iron content, using MRI R2* values in the caudate and thalamic regions in Egyptian children and young adults with SCD in comparison to beta thalassemia major (BTM) and age and sex-matched healthy controls. While the secondary objectives were to evaluate the impact of
brain iron content on neurocognitive functions assessed by neurocognitive examinations and to evaluate its association with the liver and heart iron concentrations

**Patients And Methods**

This is a cross-sectional case-control study conducted at the Pediatric Hematology Oncology department, Children's Hospital, Ain Shams University. Participation was voluntary after an informed consent and assent were obtained from legal guardians of all participants and their children. The procedures applied in this study were approved by the institutional regulatory board of the Pediatric and Radiology department as well as by the Ethical Committee of Human Experimentation of Ain Shams University and were in accordance with the Helsinki Declaration of 1975, as revised in 2008.

**Study Population:**

Thirty-two adolescents and young adults with SCD, 13 females (40.6%) and 19 males (59.4%), their mean age was $15.25 \pm 3.69$ years, were recruited at their steady state define as a point in time where the patient in question is not experiencing an acute painful crisis or any changes due to therapy). (8) In addition fifteen patients with BTM, 8 (53.3%) females and 7 (46.7%) males, their mean age $19.40 \pm 4.31$ years were recruited as a comparative iron overload syndrome. Furthermore, eleven healthy controls; subjects who had not history of any neurological disease, blood transfusion or any condition that would affect the body iron content, 6 females (54.5%) and 5 males (45.5%), their mean age was $17.73 \pm 4.84$ years.

Recruited subjects should be able to perform MRI and neuropsychiatric assessment. Subjects known to have contraindications for MRI, those with myocardial infarction, cardiac failure or and liver cell failure, those with history of neurological disease, head trauma or neurosurgery, those treated with any medications affecting the cognition, memory, behavioral were excluded. None of SCD patients had diabetes or micro-albuminuria and all of them had previously experienced vaso-occlusive crisis, clinical characteristics among the studied thirty-two SCD patients were illustrated in Table 1.

**Study Procedure:**

Patients with SCD were subjected to thorough clinical assessment with special emphasis neurological assessment and SCD related complications. The transfusion received was calculated as the transfusion index: volume of transfused packed red cells in ml per kg body weight per year (expressed as the mean value in the last two years). Thirty (93.8%) SCD patients received either mono or combined chelation therapy. Fifteen of them received mono-chelation; fourteen received oral deferiprone (DFP) in a daily dose of 50-100 mg/kg/d and one patient received deferoxamine (DFO) infused subcutaneously in a dose 30-45 mg/kg/d given 5 days/week. Compliance to chelation therapy was assessed by reviewing patient self-report of dose-taking and the appropriate number of doses taken during each day was checked by prescription refills and pill count; a cutoff point below 80% was considered as poor compliance to the regimen. (9) Of the thirty SCD patients on chelation, twenty of them received concomitantly hydroxyurea
therapy which was given orally in dose of 20 mg/kg/day with escalation to maximum tolerated dose according to the safety and response.

**Laboratory analysis**

Laboratory investigations included CBC using Sysmex XT-1800i (Sysmex, Kobe, Japan), hemoglobin analysis by HPLC using D-10 (BioRad, Marnes La Coquette, France), liver function tests (serum albumin, total and direct bilirubin, alanine aminotransferase and aspartate aminotransferase), markers of hemolysis (lactate dehydrogenase and indirect bilirubin) using Cobas Integra 800 (Roche Diagnostics, Mannheim, Germany). Serum ferritin level was measured on Immulite 1000 analyzer (Siemens Healthcare Diagnostics, Marburg, Germany) at the start of the study with calculation of the mean value of the last year prior to the study in order to estimate the ferritin trend then the cutoff value 2500 µg/L was used to classify SCD patients into 2 groups as it was defined to be the best for prediction of thalassemia complication. (10)

**Radiologic Evaluation:**

MRI examination were performed on a 1.5- Tesla super conductive MR Philips scanner (Achieva 2018, Philips, Nederland B.V., The Netherlands) at Diagnostic Radiology Department at Ain Shams University Hospital without any contrast material. Patients were prepared and were trained to remain motionless, avoid excessive swallowing and to regulate respiration and were informed that study takes about 10 -15 minutes and that the system generates some loud noise.

**Regional-brain R2* Quantitative MRI assessment** performed for fifteen SCD patients and fifteen BTM and eleven controls. Localizer images in three orthogonal planes were taken first then axial slices of the brain were acquired covering the regions of interest (ROIs) (both right and left caudate and thalamic nuclei); each slice was acquired by a multi echo gradient T2* sequence (Fast Field Echo/m-FFE) and the total acquisition time was 2.15 minutes. Sequence parameters were as follow; twelve (TEs) spaced from 1 to 12 msec, TR: 100, slice thickness=10, FOV: 225x225, Matrix size: 140x150, Flip angle= 15º and NSA=6. Drawing ROIs on the caudate head and thalamic nuclei was done manually. Then each ROI is propagated to the other (TEs), automatically. This was performed symmetrically in both hemispheres (left and right sides). The mean (SI) of a region was measured for each image and plotted against the TE. A single T2* decay curve for each ROI is obtained that generally reflect the average iron concentration in that region. The mean regional brain T2* and R2* values were calculated manually using a simple mathematical model using Microsoft (MS) Excel Spread Sheet V 2.01 where values of signal intensity (T2* values) and TEs were manually inputted into the Excel spreadsheet. (11)

**Quantitative liver iron concentration (LIC) and myocardial T2* MRI assessment** were performed for fifteen SCD and fifteen BTM only. Myocardial T2* was measured through multiecho turbo field echo black and white blood short axis and patients were then classified into normal T2* levels (>20ms), low (15-20 ms), intermediate (10-15ms), and high risk T2* < 10ms calculated. (12) LIC was performed through multi-echo
gradient axial cuts through upper abdomen. According to liver iron T2* values, patients are classified into normal T2* levels (>11.4ms), low (3.8-11.4ms), intermediate (1.8-3.8 ms), and high T2* (<1.8ms). (13)

**Neurocognitive and psychiatric assessment:**

Psychiatric interviews and assessments were conducted by experienced qualified psychologist using the following instruments.

**Wechsler Intelligence Scale for Children-Fourth Edition (WAIS-IV):** It is an intelligence quotient (IQ) test designed to measure intelligence and cognitive ability and to assess verbal comprehension, visual-perceptive performance, working memory, processing speed and finally provides a global scale to get the IQ. (14) Findings were classified as under threshold if value were <90, normal or average 90-109, over the threshold if >109. (15)

**Brief Psychiatric Rating Scale (BPRS):** 24-item BPRS (version 4.0) assesses 24 psychiatric symptoms including depression and anxiety. The presence and severity of psychiatric symptoms were rated on a Likert scale ranging from 1 (not present) to 7 (extremely severe). A separate score for the degree of pathology in each of the symptoms areas is obtained in this way. (16)

**Benton Visual Retention Test:** This is an individually administered test that measures visual perception and visual memory. It can also be used to help identify possible learning disabilities among other afflictions that might affect an individual's memory. The individual examined is shown 10 designs, one at a time, and asked to reproduce each one as exactly as possible on plain paper from memory. The test is untimed, and the results are professionally scored by form, shape, pattern, and arrangement on the paper. Test has cut of point at ≥4 and those values are the same for the difference between the obtained correct and the expected correct, and the difference between the obtained error and expected error. (17)

**Statistical analysis:**

Data were entered, processed and analyzed using software IBM® SPSS® Statistics 23 version. Descriptive statistics for quantitative variables were described as mean and standard deviation or median and interquartile range (IQR; 75th and 25th percentiles). Qualitative variables were described as number and percent. Kolmogrov Smirnov test was used for testing the distribution of normality. T-test was used to compare between two groups for numerical variables and Chi square test for categorical variables. The comparison between two independent groups with qualitative data was performed using Chi-square test and the comparison between more than two independent groups with quantitative data and parametric distribution was performed by One Way ANOVA test followed by post hoc analysis using LSD test. Pearson correlation coefficients were used to assess the correlation between two quantitative parameters in the same group. The confidence interval was set to 95% and the margin of error accepted was set to 5%, the probability of <0.05 was used as a cutoff point for significant test meaning that P-value <0.05 were significant.
**Results**

Neurocognitive and psychiatric characteristics among the studied patients with SCD were illustrated in Table 2. Nearly two third of SCD had IQ under-threshold (IQ value <90). 12.5% of SCD patients had moderate to severe anxiety and 60.8% had of SCD patients had depression.

Only two male patients with SCD had history of stroke; with headache in one patient and limb weakness affecting the left side in the other patient were the presenting symptoms. Both had confirmed radiological diagnosis of stroke showing lacunar infarctions (watershed infarctions). At the time of assessment, both had no functional neurological deficit and normal TCD assessment.

Radiological characteristics of the studied groups are illustrated in Table 3. There were no significant differences between the three studied groups with respect to age ($p=0.261$). Left thalamus R2* value was higher in patients with BTM than both patients with SCD and healthy controls.

Correlation study between R2* values of different regions of brain in patients with SCD and the studied neurocognitive parameters showed no significant correlation except positive correlation between left caudate R2* and anxiety value ($r=0.724$, $p=0.012$). There were positive correlation between hemoglobin S% and both left caudate R2* ($r=0.015$, $p=0.031$) and right thalamus R2* ($r=0.612$, $p=0.105$) and a negative correlation between hemoglobin A% and left caudate R2* ($r=-0.568$, $p=0.027$). There were positive correlation between left caudate R2* and age, negative correlation between transfusion index and right thalamus R2* as shown in Figure 1. However there was non-significant correlation between mean pre-transfusion hemoglobin and the R2* values of different regions of brain.

A univariate linear regression model was built between certain variables (age, transfusion frequency, Hb S%, Hb A%, Benton visual retention test) and the left caudate R2* showed that the most important factor influenced by the level of left caudate R2* is the Benton visual retention for the difference of correct ($t=5.687$, $p=0.011$).

The correlation coefficients between R2* values of different regions of brain in SCD subgroup with patients’ showed no significant association was found between brain R2* values LIC or heart R2* values. R2* values of different regions of brain in relation with the studied parameters of patients with SCD was not significant except for sex; mean right caudate R2* value was higher in female (17.38 ± 0.83) than in male (15.58 ± 1.68) ($p=0.044$).

**Illustrative case**

Seventeen years old female patient with SCD, on regular blood transfusion, had serum ferritin level equal 7426 ng/ml. Her liver iron content equals 7.49 mg/g, cardiac T2* equals 41 ms, cardiac R2* equals 24.4 Hz and her calculated MIC equal 0.48 mg/g. Figure 2 showed that her estimated left thalamus T2* was 69.1 ms, R2* 14.5 Hz and calculated left thalamus R2* was 14.5 Hz (within the normal range of R2* of healthy controls (13.3-16.9)).
Discussion

Sickle cell disease (SCD) is common among people from Africa, the Middle East, and the Mediterranean. (18) Although the wider use of hydroxycarbamide and newer therapeutic approaches offer hope for decreased mortality and improved health related quality of life, SCD in lower source countries still carries poor prognosis and associated with high early childhood mortality. (19) Transfusion is a frequently employed therapy in SCD, but its best-validated uses have been in preoperative prophylaxis, treatment of acute chest syndrome (ACS), prophylaxis and treatment of stroke (20) and nearly more than 90% of adults are receiving at least one transfusion in their lifetimes. (19) While transfusion may improve disease complications, iron overload is an inevitable consequence of transfusion therapy and iron deposited in the different body organs leading to their cellular damage. (21) Chronically transfused iron overloaded patients with SCD have significantly higher mortality than less transfused counterparts without iron overload. (22)

Studies and data concerning the brain iron deposition in SCD patients are still limited and conflicting. Multiple studies showed increased iron levels in certain brain regions which were normal in the other studies. Although MRI is the most reliable and non-invasive method for early detection of the organic iron overload with sensitivity of 96% and specificity of 80% (23), there are still no international guidelines that set the cut off values of brain R2* values for the brain iron assessment in patients with iron overload as those established in the liver and heart. Anatomical networks are mostly studied using a model-driven seed-based approach with a priori hypotheses of manually selected regions of interest and their connected networks. (24-25) The basal ganglia and thalamus were chosen to be the region of interest (ROIs) as they are known to be the main sources of brain iron accumulation. (26-27)

A 2D T2* multiecho fast gradient echo pulse sequences was used in the current study for assessment of brain iron content, same technique used by Akhlaghpoor and his team (5) while other researchers used a 3D gradient-echo sequence. (28) Early study showed that R2* is more sensitive to R2 in evaluation of the brain iron content comparing both to chemically determined brain iron concentrations in a postmortem study. (29) Subsequent study found that SWI was the most sensitive in detecting iron accumulation in the choroid plexus, followed by GRE T2* sequence in comparison to T2-weighted. (30)

Early in 2000s the first study was performed to evaluate the MRI brain iron content in patients with BTM; the study found that the T2 relaxation rates (R2) were higher in the caudate, putamen, motor and temporal cortex in BTM patients than in the controls. (31) A decade later, another study confirmed that BTM patients had significantly lower T2* values in basal ganglia, thalamus and adenohypophysis compared to controls and no correlation between liver T2* values and T2* values of basal ganglia (striatum) and the thalamus. (5) In 2018, a study found that BTM patients showed significantly higher susceptibility value in the red nucleus and choroid plexus indicating more iron deposition in both areas. (28) In the same year, another study used voxel based high resolution whole brain MRI study in addition to regional analysis of the grey matter subcortical regions. In this study, compared to the controls group, both TDT (transfusion dependent thalassemia) and NTDT (non- transfusion dependent thalassemia)
groups show only small areas of higher iron deposition; these areas were the anterior hippocampal formation, areas around Luschka foramina and dorsal thalamic nuclei (in TDT; left thalamic region). (32)

In 2014 Brown et al. found that only the choroid plexus which showed significant increase in iron content in the SCD group, and the levels correlated well with serum ferritin and liver R2* while no significant iron elevation in the subcortical nuclei and no correlation between the iron levels in the subcortical structures and the liver R2* when corrected for age. (33) In 2018, Miao et al. measured the brain iron content of the asymptomatic SCD patients using R2*-regional based brain iron quantification including caudate nucleus, putamen, globus pallidus, red nucleus, substantia nigra, and the dentate nucleus, and found that only the R2* values of the substantia nigra and the dentate nucleus were significantly higher in the SCD group than the controls. (34)

In the current study, three subgroups that performed MRI assessment were age and sex matched. No significant differences were found between the SCD and control groups in all regions including the left thalamus. However, in BTM subgroup, patients had significantly higher R2* values compared to the controls and SCD patients as regards to the left thalamic region. There is conflicting result as regard differential iron content; one research concluded that left hemisphere showed greater iron content than the right hemisphere (27) while other found that there was no significant differences between both hemispheres. (31) Our study showed no correlation between the measured R2* values in all the selected ROIs and liver iron concentrations in in both SCD and BTM patients, which may indicate that LIC is not good indicator of the brain iron content. Also, our study showed that no significant correlation was found between the serum ferritin and R2* values in all selected ROIs in SCD group. In general, most of the studies indicate that serum ferritin as well as LIC and MIC are not good predictors of brain iron overload. (5, 32-33)

The different findings in different studies regarding brain iron content could be explained by the hypothesis that the brain has a protective mechanism against iron overload by decreasing the transferrin receptors when the serum iron level increases. So iron deposition cannot exceed certain saturation level in certain brain areas. Also differences in the T2* values among the various brain regions indicates that the iron uptake into the brain differs depending on the brain region. (5, 31) Differences could also be explained by sample characteristics; different demography, environmental and dietary factors and guidelines of treatment in different countries with different chelation therapy as well as different study design and MRI sequences.

The Cooperative Study of Sickle Cell Disease (CSSCD) began examining neurocognitive function and neuroimaging patterns in a large SCD cohort over a 10-year period. The CSSCD found that nearly 22% of children with HbSS experienced a clinical stroke or silent cerebral infarct prior to 15 years of age, and that there were measureable differences in global cognitive function and specific neuropsychological function associated with these events. (35) In addition, the CSSCD found that in children who had no evidence of brain abnormality on MRI over the 10 years of participation, there was still a mean decline of 16 IQ points over time. (36) This strongly suggested that something besides vascular occlusion/infarction placed
children with SCD at risk, and mechanisms involving chronic anemia, hypoxia or interference with oxygen perfusion and diffusion have been considered. (37) A literature review in 2007 revealed there was a decrease in the neurocognitive functions in SCD patients evidenced by impairment in Full Scale IQ (FSIQ), Verbal IQ (VIQ) or Performance IQ (PIQ) and impaired attention and executive functions together with academic achievement. (38) Children with SCD are at a high risk for neurocognitive impairment, which has potential implications for overall HRQL. A meta-analysis indicated that children with SCD often scored lower on general IQ measures than healthy children, with 51% of studies reporting significant differences. When examining specific cognitive abilities, more robust and consistent differences were found, with 71% of studies reporting significant deficits in at least one cognitive domain. (39) Deficits have been found most often in attention, processing speed, and working memory, as well as verbal and language domains. (36, 40) In agreement with previous studies, our study showed that 68.9 % of our SCD patients had under threshold TIQ scores. Furthermore 50% of the patients showed mild anxiety, 8.3% moderate anxiety and 4.3% showed severe anxiety.

Reasons behinds cognitive dysfunctions in SCD patients are still not fully understood. Despite, we reported cognitive dysfunctions in SCD patients, there were no statistically significant differences between the SCD and control groups as regard the brain iron deposition. Previous studies showed that these neurological abnormalities may be due to neurotoxicity of DFO, chronic hypoxia, chronic illness, multiple hospitalizations or silent strokes. (2,3)

With the study limitations, the relative small sample size, the lack of comparative neurocognitive tests for BTM cohort, the usage of ME-GRE T2* sequence and not the susceptibility weighted images sequence (SWI), and the lack of whole brain quantitative MRI study, we conclude that the brain iron deposition as the solo cause for neurocognitive impairment in patients with SCD could not be proved.

**Abbreviations**

| Abbreviation                                    | Full name            |
|-------------------------------------------------|----------------------|
| Central nervous system                          | CNS                  |
| Sickle cell disease                             | SCD                  |
| Reactive oxygen species                         | ROS                  |
| Liver iron concentration                        | LIC                  |
| Regions of interest                             | ROIs                 |
| Wechsler Intelligence Scale for Children-Fourth Edition | WAIS-IV             |
| Brief Psychiatric Rating Scale                  | BPRS                 |

**References**
1. Ohene-Frempong K. Stroke in sickle cell disease: Demographic, clinical, and therapeutic considerations. Seminars in Hematology 1991; 28(3): 213–219.

2. Brown RT, Davis PC, Lambert R, Hsu L, Hopkins K, Eckman J. Neurocognitive functioning and magnetic resonance imaging in children with sickle cell disease. J Pediatr Psychol 2000; 25(7):503-13.

3. Vichinsky EP, Neumayr LD, Gold JI, Weiner MW, Rule RR, Truran D, Kasten J, Eggleston B, Kesler K, McMahon L, Orringer EP, Harrington T, Kalanyak K, De Castro LM, Kutlar A, Rutherford CJ, Johnson C, Bessman JD, Jordan LB, Armstrong FD; Neuropsychological Dysfunction and Neuroimaging Adult Sickle Cell Anemia Study Group. Neuropsychological dysfunction and neuroimaging abnormalities in neurologically intact adults with sickle cell anemia. JAMA 2010;303(18):1823-31.

4. Hare D, Ayton S, Bush A, Lei PA. A delicate balance: Iron metabolism and diseases of the brain. Front Aging Neurosci, 2013;5:34.

5. Akhlaghpour S, Ghahari A, Morteza A, Khalilzadeh O, Shakourirad A, Alinaghizadeh MR. Quantitative T2* magnetic resonance imaging for evaluation of iron deposition in the brain of β-thalassemia patients. Clin Neuroradiol. 2012; 22(3):211-7.

6. Thompson BW, Miller ST, Rogers ZR, Rees RC, Ware RE, Waclawiw MA, Iyer RV, Casella JF, Luchtman-Jones L, Rana S, Thornburg CD, Kalpathi RV, Barredo JC, Brown RC, Sarnai K, Howard TH, Luck L, Wang WC. The pediatric hydroxyurea phase III clinical trial (BABY HUG): challenges of study design. Pediatr Blood Cancer 2010;54(2):250-5.

7. Steinberg MH, McCarthy WF, Castro O, Ballas SK, Armstrong FD, Smith W, Ataga K, Swerdlow P, Kutlar A, DeCastro L, Waclawiw MA; Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia and MSH Patients' Follow-Up. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up. Am J Hematol. 2010;85(6):403-8.

8. Ballas SK, Lieff S, Benjamin LJ. Definitions of the phenotypic manifestations of sickle cell disease. Am J Hematol 2010; 85:6–13.

9. Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, Ollendorf DA, Wong PK. Medication Compliance and Persistence: Terminology and Definitions. Value Health 2008; 11:44-47.

10. Silvilairat S, Sittiwangkul R, Pongprot Y, Charoenkwan P, Phomphutkul C. Tissue doppler echocardiography reliably reflects severity of iron overload in pediatric patients with beta thalassemia. Eur J Echocardiogr 2008; 9:368–372

11. Fernandes JL, Sampaio EF, Verissimo M, Pereira FB, Alvaro da Silva J, de Figueiredo GS, Kalaf JM, Coelho OR. Heart and liver T2* assessment for iron overload using different software programs. European Radiology 2011; 21:2503-2510.

12. Carpenter JP, He T, Kirk P, Roughton M, Anderson LJ, de Noronha SV, Sheppard MN, Porter JB, Walker JM, Wood JC, Galanello R, Forni G, Catani G, Matta G, Fucharoen S, Fleming A, House MJ, Black G, Firmin DN, St Pierre TG, Pennell DJ. On T2* magnetic resonance and cardiac iron. Circulation 2011;123(14):1519-28.
13. Garbowski MW, Carpenter JP, Smith G, Roughton M, Alam MH, He T, Pennell DJ, Porter JB. Biopsy-based calibration of T2* magnetic resonance for estimation of liver iron concentration and comparison with R2 Ferriscan. J Cardiovasc Magn Reson. 2014;16(1):40.

14. Wechsler D. Wechsler intelligence scale for children – Fourth edition (WISC-IV). San Antonio, TX: The Psychological Corporation 2003.

15. Weiss LG, Saklofske DH, Prifitera A, Holdnack JA. WISC-IV Advanced Clinical Interpretation. Burlington (MA): Academic Press 2006.

16. Ventura J, Lukoff D, Nuechterlein KH, Liberman RP, Green M, Shaner A. Brief Psychiatric Rating Scale (BPRS) Expanded version (4.0) scales, anchor points and administration manual. International Journal of Methods in Psychiatric 1993;3:227–244.

17. Benton AL. Benton Visual Retention Test (5th ed.). San Antonio: The Psychological Corporation 1992.

18. Agha M, Eid AF and Sallam M. Sickle cell anemia: Imaging from head to toe. The Egyptian Journal of Radiology and Nuclear Medicine 2013; 44: 547–561.

19. Ware RE, Montalembert MD, Tshilolo L, Abboud MR. Sickle cell disease. The Lancet 2017; 390: 311 – 323.

20. Raghupathy R, Manwani D, Little JA. Iron Overload in Sickle Cell Disease. Advances in Hematology 2010; 1-10.

21. Fibach E, Rachmilewitz EA. Iron overload in hematological disorders. Presse Med. 2017; 46(12 Pt 2):e296-e305.

22. Fung EB, Harmatz P, Milet M, Ballas SK, De Castro L, Hagar W, Owen W Olivieri N, Smith-Whitley K, Darbari D, Wang W, Vichinsky E and the Multi-Center Study of Iron Overload Research Group. Morbidity and mortality in chronically transfused Subjects with Thalassemia and Sickle Cell Disease. American Journal of Hematology 2007; 82:255-265.

23. Farhangi H, Badiei Z, Moghaddam HM, Keramati MR. Assessment of Heart and Liver Iron Overload in Thalassemia Major Patients Using T2* Magnetic Resonance Imaging. Indian J Hematol Blood Transfus. 2017; 33(2):228–234.

24. Zielinski BA, Anderson JS, Froehlich AL, Prigge MB, Nielsen JA, Cooperrieder JR, Cariello AN, Fletcher PT, Alexander AL, Lange N, Bigler ED, Lainhart JE. scMRI reveals large-scale brain network abnormalities in autism. PLoS One. 2012; 7(11):e49172.

25. Soriano-Mas C, Harrison BJ, Pujol J, López-Solà M, Hernández-Ribas R, Alonso P, Contreras-Rodríguez O, Giménez M, Blanco-Hinojo L, Ortiz H, Deus J, Menchón JM, Cardoner N. Structural covariance of the neo striatum with regional gray matter volumes. Brain StructFunct 2013; 218(3):697-709.

26. Argyropoulou MI, Metafratzi Z, Kiortsis DN, Bitsis S, Tsatsouls A, Efremidis S. T2 relaxation rate as an index of pituitary iron overload in patients with beta-thalassemia major. AJR Am J Roentgenol. 2000; 175:1567–9.
27. Xu X, Wang Q, Zhang M. Age, gender, and hemispheric differences in iron deposition in the human brain: an in vivo MRI study. Neuroimage 2008; 40:35–42.
28. Qiu D, Chan GC, Chu J et al. MR quantitative susceptibility imaging for the evaluation of iron loading in the brains of patients with β-thalassemia major. AJNR Am J Neuroradiol. 2014; 35(6):1085-90.
29. Langkammer C, Krebs N, Goessler W, Scheurer E, Ebner F, Yen K, Fazekas F, Ropele S. Quantitative MR imaging of brain iron: a postmortem validation study. Radiology 2010;257(2):455-62.
30. Hasiloglu ZI, Asik M, Ure E, Ertem F, Apak H, Albayram S. The utility of susceptibility-weighted imaging to evaluate the extent of iron accumulation in the choroid plexus of patients with β-thalassaemia major. Clin Radiol. 2017;72(10):903.e1-903.e7.
31. Metafratzi Z, Argyropoulou MI, Kiortsis DN, Tsampoulas C, Chaliassos N, Efremidis SC. T(2) relaxation rate of basal ganglia and cortex in patients with beta-thalassaemia major. Br J Radiol. 2001;74(881):407-10.
32. Tartaglione I, Perrotta S, Caiazza M, Casale M, Di Concilio R, Ciancio A, De Michele E, Amendola G, Gritti P, Carafa PA, Ferrantino T, Centanni A, Ippolito N, Caserta V, Oliveto T, Granato I, Femina G, Esposito F, Ponticorvo S, Russo A, Russo C, Cirillo M, Elefante A, Manara R. Cerebral Iron Overload In Beta Thalassemia: Does It Really Matter? Poster session presented at the 23rd Annual Congress of European Hematology Association, Stockholm, 2018 (June 16).
33. Brown RC, Qiu D, Hayes L, Barry V, Jones R. Quantitation of Iron in Brain Structures of Children with Sickle Cell Disease and Transfusion Hemosiderosis. Blood 2014; 124 (21):1393.
34. Miao X, Choi S, Tamrazi B., Chai Y, Vu C, Coates TD, Wood JC. Increased brain iron deposition in patients with sickle cell disease: an MRI quantitative susceptibility mapping study. Blood 2018; 132(15):1618-1621.
35. Armstrong FD, Thompson RJ Jr, Wang W, Zimmerman R, Pegelow CH, Miller S, Moser F, Bello J, Hurtig A, Vass K. Cognitive functioning and brain magnetic resonance imaging in children with sickle Cell disease. Neuropsychology Committee of the Cooperative Study of Sickle Cell Disease. Pediatrics. 1996 Jun;97(6 Pt 1):864-70.
36. Wang W, Enos L, Gallagher D, Thompson R, Guarini L, Vichinsky E, Wright E, Zimmerman R, Armstrong FD; Cooperative Study of Sickle Cell Disease. Neuropsychologic performance in school-aged children with sickle cell disease: a report from the Cooperative Study of Sickle Cell Disease. J Pediatr. 2001 Sep;139(3):391-7.
37. Armstrong FD, Pavlakis S, Goldman ML, Thompson W, Cuadra A, Sulc W. Neurocognitive outcomes in sickle cell disease. In: Cognitive and Behavioral Abnormalities of Pediatric Diseases. Nass R, Frank Y (Eds). Oxford University Press, NY, USA 2010: 285–292.
38. Berkelhammer LD, Williamson AL, Sanford SD, Dirksen CL, Sharp WG, Margulies AS, Prengler RA. Neurocognitive sequelae of pediatric sickle cell disease: a review of the literature. Child Neuropsychol. 2007;13(2):120-31.
39. Schatz J, Finke RL, Kellett JM, & Kramer JH. Cognitive functioning in children with sickle cell disease: A meta-analysis. Journal of Pediatric Psychology 2002; 27: 739-748.
Tables

Table 1: Clinical and laboratory characteristics of the studied patients with sickle cell disease

| Clinical characteristics                      | Sickle Cell disease patients No. = 32 |
|----------------------------------------------|---------------------------------------|
| **Therapeutic modalities**                   |                                       |
| Transfusion frequency/ month; Median (IQR)   | 2 (1 – 3)                             |
| Transfusion Index (ml/Kg/year); Mean ± SD    | 174.70 ± 63.98                        |
| Iron Overload/day (mg/kg); Mean ± SD         | 0.30 ± 0.12                           |
| **Co-morbidities**                           |                                       |
| Delayed puberty                              | 5 (15.6)                              |
| Crisis frequency >3 / year                   | 10 (31.3)                             |
| Splenectomy                                  | 12 (37.5)                             |
| Hepatitis C Virus infection                  | 4 (12.5)                              |
| Cardiopulmonary complications               | 3 (9.4)                               |
| Acute chest syndrome                         | 6 (18.8)                              |
| Stroke                                       | 2 (6.3)                               |
| **Laboratory data**                          |                                       |
| Pre-transfusion hemoglobin (g/dL); Mean ± SD | 8.52 ± 1.79                           |
| HbS %; Median (IQR)                          | 61.40 (51.55-78.2)                    |
| HbF %; Median (IQR)                          | 8 (3.65 - 15.31)                      |
| HbA %; Median (IQR)                          | 25.5 (9.15 - 41.35)                   |
| Serum ferritin (ng/ml); Median (IQR)         | 2819.50 (1194.2 - 4500)               |
| Serum Ferritin: Cutoff > 2500ng/ml; n (%)    | 17 (56.7)                             |
| Alanine aminotransferase (U/L); Mean ± SD    | 25.5 (13 – 33)                        |
| Aspartate aminotransferase (U/L); Mean ± SD  | 46.93 ± 20.50                         |
| Total bilirubin mg/dL; Median (IQR)          | 2.5 (2 – 3.8)                         |
| Direct bilirubin mg/dL; Median (IQR)         | 0.9 (0.78 – 1.2)                      |
| Albumin g/dL; Mean ± SD                      | 4.25 ± 0.31                           |
| Serum creatinine mg/dL; Mean ± SD            | 0.34 ± 0.11                           |
| Lactate dehydrogenase (IU/L); Mean ± SD      | 532.98 ± 246.24                       |
| Amylase U/L; Mean ± SD                       | 58.03 ± 17.00                         |
### Table 2: Neurocognitive and psychiatric characteristics among patients with sickle cell disease

| Wechsler Intelligence Scale Fourth Edition (WAIS-IV) | Sickle Cell disease n = 29 |
|-----------------------------------------------------|---------------------------|
| Verbal; Mean ± SD (Range)                           | 89.55 ± 10.34 (75 – 118) |
| Perceptual; Mean ± SD (Range)                       | 85.41 ± 9.11 (71 – 106)  |
| Memory; Mean ± SD (Range)                           | 88.66 ± 12.81 (67 – 125) |
| Processing; Mean ± SD (Range)                       | 88.38 ± 13.32 (70 – 116) |
| Total IQ; Mean ± SD (Range)                         | 86.97 ± 10.16 (74 – 113) |
| WAIS-IV Category                                   |                           |
| Under-threshold (<90)                               | 20 (68.9%)                |
| Average (90-109)                                   | 8 (27.5%)                 |
| Over-threshold (>109)                               | 1 (3%)                    |

| Benton Visual Retention Test | Sickle Cell disease n = 19 |
|------------------------------|---------------------------|
| Mean ± SD (Range) Obtained correct | 4.65 ± 2.00 (1 – 8) |
| Expected correct; Mean ± SD (Range)       | 6.00 ± 1.83 (2 – 8) |
| Difference; Mean ± SD (Range)             | 2.50 ± 1.15 (1 – 5) |
| Obtained error; Median (IQR)             | 5 (3 – 6)                |
| Expected error; Mean ± SD (Range)        | 6.21 ± 2.70 (3 – 12) |
| Difference; Median (IQR)                 | 3 (1 – 4)                |

| Anxiety test | Sickle Cell disease n = 24 |
|--------------|---------------------------|
| Anxiety value; Median (IQR)            | 8.5 (5.5 – 12)            |
| Anxiety Category |                           |
| Normal        | 9 (37.5%)                 |
| Mild          | 12 (50.0%)                |
| Moderate      | 2 (8.3%)                  |
| Severe        | 1 (4.2%)                  |

| Depression test | No. = 24 |
|-----------------|----------|
| Depression Value; Median (IQR) | 6.5 (4.5 – 10.5) |
| Depression Category |               |
| Normal          | 9 (39.2%)  |
| Mild            | 3 (13.0%)  |
| Moderate        | 11 (47.8%) |

### Table 3: Radiological assessment of the studied groups
### Regional-brain R2* MRI

|                | Sickle cell disease n= 15 | B thalassemia major n= 15 | Controls n = 11 | Test value* | P-value |
|----------------|---------------------------|---------------------------|------------------|-------------|---------|
| Lhgt thalamus R2*; Mean ± D | 15.65 ± 1.02              | 16.35 ± 1.19              | 15.93 ± 1.21     | 1.415       | 0.256   |
| Lft thalamus R2*; Mean ± D  | 15.79 ± 0.77               | 16.69 ± 1.34              | 15.65 ± 1.10     | 3.761       | 0.032   |
| Lhgt caudate R2*; Mean ± D  | 16.18 ± 1.67               | 16.05 ± 2.69              | 16.76 ± 2.76     | 0.311       | 0.735   |
| Lft caudate R2*; Mean ± D   | 16.37 ± 1.97               | 15.27 ± 2.81              | 16.25 ± 2.25     | 0.933       | 0.402   |

### Liver and Cardiac MRI

|                | Sickle cell disease n= 32 | B thalassemia major n= 15 | Test value* | P-value |
|----------------|---------------------------|---------------------------|-------------|---------|
| LIC mg/gm; Median (IQR) | 7.56 (5.91–15.05)        | 9.52 (8.06–15.51)        | -1.637      | 0.102   |
| Liver iron concentrations (LIC); mg/gm | Normal (<2) | 0 (0%) | 0 (0%) |
|                     | Mild (2-7) | 14 (43.75%) | 1 (6.67%) |
|                     | Moderate (7-15) | 10 (31.25%) | 8 (53.33%) |
|                     | Severe (>15) | 8 (25.00%) | 6 (40.00%) |
| Heart T2*; Mean ± SD | 33.54 ± 5.64 | 43.28 ± 24.83 | -2.066      | 0.045   |
| Myocardial iron concentrations mg/gm | Normal (<1.16) | 30 (100%) | 12 (80%) |
|                     | Mild (1.16-1.65) | 0 (0%) | 0 (0%) |
|                     | Moderate (1.65-2.71) | 0 (0%) | 2 (13.3%) |
|                     | Severe (>2.71) | 0 (0%) | 1 (6.6%) |

*: Independent t-test; ‡: Mann Whitney test  *: Chi-square test; •: One Way ANOVA test

**Figures**
Figure 1

Correlations analysis among sickle cell disease; A. right thalamus R2* and transfusion index, B. left caudate R2* and age

Figure 2

Multi-echo fast gradient echo brain MRI T2* sequence. Left: Region of interest is drawn at the left thalamus (highlighted in red) for measuring the mean signal intensity throughout multiple echo times to calculate the R2*. Right: Data analysis using Microsoft Excel Spread Sheet V 2.01: the signal intensity (TE) is plotted against multiple TE values. The exponential signal decay curve is then constructed. T2* and R2* values are calculated automatically in the left thalamic region.